Kennedy Wilson Acquires 124-Unit Northbank Apartments in Dublin, Ireland for €45 Million
Global real estate investment company Kennedy Wilson (NYSE: KW) announces that it has acquired Northbank Apartments, a wholly-owned 124-unit apartment community in Dublin’s North Docks, for €45 million from Jarmar Properties Limited (In Receivership) acting through David Carson of Deloitte as Statutory Receiver, the lender being the National Asset Management Agency (“NAMA”).
Situated in Dublin’s North Docks, Northbank is located just 50 meters from Kennedy Wilson’s existing 84-unit Liffey Trust apartments. The two buildings benefit from great transport links as the LUAS Red line is immediately adjacent connecting to Dublin’s city centre and main train stations in five minutes.
“The successful acquisition of Northbank in such close proximity to our Liffey Trust asset allows us to leverage our existing presence and implement our value-add asset management strategy, including adding onsite management and amenities to serve both properties. We believe we have a great opportunity to grow our near-term NOI by undertaking additional refurbishments to enhance Northbank’s rental growth prospects,” said Mary Ricks, President and CEO of Kennedy Wilson Europe.
“We are particularly pleased to secure Northbank as one of the few remaining unbroken 100+ unit multifamily assets left to trade in Dublin. The North Docks is a rapidly expanding sub market where we want to grow our footprint. This is all part of our exciting plans to more than double our multifamily business in Europe to 5,000 units over the next few years,” added Ricks.
Completed in 2007, Northbank includes 31 one-bedroom, 64 two-bedroom and 29 three-bedroom apartments (of which 75% are occupied or with leases agreed), secure underground car parking and 16,000 sq ft of currently vacant retail space. It benefits from significant development in the area, with nearly 2 million sq ft of new office buildings either under construction or planned for this sub-market.
About Kennedy Wilson
Kennedy Wilson (NYSE:KW) is a global real estate investment company. We own, operate, and invest in real estate both on our own and through our investment management platform. We focus on multifamily and commercial properties located in the Western U.S., UK, Ireland, Spain, Italy and Japan. To complement our investment business, the Company also provides real estate services primarily to financial services clients. For further information on Kennedy Wilson, please visit: www.kennedywilson.com.
Special Note Regarding Forward-Looking Statements
Statements in this press release that are not historical facts are “forward-looking statements” within the meaning of U.S. federal securities laws. These forward-looking statements are estimates that reflect our management’s current expectations, are based on assumptions that may prove to be inaccurate and involve known and unknown risks. Accordingly, our actual results or performance may differ materially and adversely from the results or performance expressed or implied by these forward-looking statements, including for reasons that are beyond our control. For example, we may not be able to maintain our current acquisition or disposition pace or identify future properties to acquire on terms we consider attractive, and our current property portfolio may not perform as expected. Accordingly, you should not unduly rely on these statements, which speak only as of the date of this press release. We assume no duty to update the forward-looking statements, except as may be required by law.
KW-IR
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171215005053/en/
Contact information
Investors:
Kennedy Wilson
Daven Bhavsar, CFA
Director
of Investor Relations
+1 (310) 887-3431
dbhavsar@kennedywilson.com
or
Media:
United
States
Kennedy Wilson
Emily Heidt
Director of Public
Relations
+1 (310) 887-3499
eheidt@kennedywilson.com
or
Ireland
Q4
Public Relations
Martin Mackin
+353 1 475 1444
martin@q4pr.ie
or
UK
FTI
Consulting
Dido Laurimore / Tom Gough
+44 20 3727 1000
kennedywilson@fticonsulting.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Intends to Buy Back approximately 2.4 Million Shares in the Context of the Accelerated Bookbuild Offering by EQT, ADIA and Auba27.5.2025 18:46:00 EEST | Press release
Galderma Group AG (SWX:GALD): Ad hoc announcement pursuant to Art. 53 LR Galderma intends to repurchase approximately 2.4 million shares in the context of the accelerated bookbuild offering of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (“ADIA”) and Auba Investment Pte. Ltd. (“Auba”) announced today The repurchased shares will be held in treasury and financed by existing liquidity at hand Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it intends to repurchase approximately 2.4 million Galderma shares in the context of an accelerated bookbuilding offering (“ABO”) of approximately 16.7 million Galderma shares (approximately 7% of Galderma’s share capital) by EQT, ADIA and Auba. Galderma will participate in the ABO at the same price per share which will be determined in the bookbuilding. The repurchased shares will be financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to de
New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration27.5.2025 18:44:00 EEST | Press release
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. The Minister’s visit highlights a deepening collaboration between South Korea and Australia in the field of clinical research and highlights the strategic importance of cross-border partnerships in advancing global drug development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527294947/en/ Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong,
LambdaTest Introduces Automation MCP Server to Revolutionize Test Failure Triaging27.5.2025 18:00:00 EEST | Press release
LambdaTest, a unified agentic AI and cloud engineering platform, has announced the launch of its Automation MCP Server, a breakthrough solution designed to simplify and accelerate the process of triaging test failures. By enabling direct integration between AI assistants and LambdaTest’s test execution data, the Automation MCP Server empowers developers and QA engineers to investigate and resolve issues faster, without leaving their integrated development environment (IDE). The Automation MCP Server offers a seamless interface within the IDE, allowing users to access and analyze real-time test data with ease. With intelligent root cause analysis, the MCP server can quickly identify the underlying reasons for test failures and take immediate action to fix the underlying code. This results in fewer debugging cycles and faster release times. The server also enhances automated testing workflows by enabling the generation of new test cases using real execution data. Developers can leverage
The Six Winning Projects of the 12 th Edition of the IBSA Foundation Fellowships have been Awarded and the 2025 Call is Now Open27.5.2025 17:58:00 EEST | Press release
Research means investing in the future. This is the guiding principle behind the IBSA Foundation Fellowships programme, which for over a decade has supported talented researchers under 40 from universities and research institutions around the world. The programme awards grants to promote innovative and potentially groundbreaking projects in lesser-explored scientific fields; a constantly growing success, also confirmed by the 2024 edition, which marked a new record, with 259 applications across five scientific areas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522244202/en/ The Award Ceremony of the 12th edition of the IBSA Foundation Fellowship The € 32,000 fellowships were awarded to research projects in five scientific areas: dermatology, endocrinology, fertility/urology, pain medicine/orthopaedics/rheumatology and healthy aging/regenerative medicine. In particular, this latter category has attracted growing interes
Rigaku Completes New Building at Yamanashi Plant27.5.2025 17:00:00 EEST | Press release
Rigaku Corporation, a global solution partner in X-ray analytical technologies and a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami; hereinafter “Rigaku”) completed an additional manufacturing building (hereinafter “the New Building”) at Yamanashi Plant, Rigaku’s main production facility. The facility was established to serve as the center of Rigaku’s production framework, in anticipation of global business growth and expansion in product demand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527974928/en/ Exterior view of the New Building, Yamanashi Plant Doubling of production capacity: a strategic base to support Rigaku’s growth Demand for X-ray analytical solutions has soared in recent years, both in Japan and worldwide. To respond to growing demand, Rigaku implemented this expansion with two key objectives in mind. One objective is to further reinforce the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom